Device Trial Radar · NCT06910592
EXOMIND (BTL-995) for Reduction of Binge-eating
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Jul 26, 2023
Primary completion
Dec 15, 2023
Study completion Mar 11, 2024
Sponsor
- Lead sponsor
- BTL Industries Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 4, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if the treatment with the BTL-995-rTMS device is able to reduce binge eating in adults above the age of 22 years. The main question it aims to answer is: Whether the treatment with the BTL-995-rTMS device reduces binge eating. Participants will be asked to: Undergo six treatments Undergo weight measurements Complete the Binge Eating Scale Complete the Therapy Comfort Questionnaire Complete the Satisfaction Questionnaire
Conditions
- Binge-Eating Disorder
Interventions
Treatment with BTL-995-rTMSDevice
Six transcranial magnetic stimulation treatments with the BTL-995-rTMS device will be delivered over the left dorsolateral prefrontal cortex, spaced 2 to 4 days apart. The intensity will be adjusted according to the subject's feedback, up to 70% of the individual's motor threshold.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Change in Binge EatingTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Center "Intermedica"
Sofia, Bulgaria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.